Addiction science & clinical practice
April 11, 2013
Yasuko Fuse-Nagase, Toru Nishikawa
14 citations
A 30-year-old Japanese man with no prior psychiatric history developed delusions lasting 2 months after abusing 5-MeO-DIPT (Foxy) and later a legal aromatic liquid used recreationally. His condition improved but relapsed 6 months later with prolonged delusions after again ingesting the aromatic liquid. The chronological sequence suggests that the aromatic liquids, easily purchased online, likely triggered the delusional episodes. The authors speculate that recurrent 5-MeO-DIPT abuse caused sensitization (reverse tolerance), amplifying the response and prolonging delusions. This sensitization may be a latent factor in subsequent drug-induced psychosis, and psychiatrists should consider it when evaluating acute psychosis patients.
Addiction science & clinical practice
August 29, 2024
Lucinda A Grande, Tom Hutch, Keira Jack et al.
6 citations
A sub-dissociative dose of ketamine, self-administered sublingually, helped patients with opioid use disorder complete buprenorphine initiation in an outpatient setting. Over 14 months, 37 patients were prescribed 4-8 doses of sublingual ketamine 16 mg. Among the 24 patients who reported trying ketamine, 16 (67%) completed buprenorphine initiation, and 11 of the last 12 completers (92%) remained in treatment for 30 days. Most patients reported reduced or eliminated spontaneous withdrawal symptoms, and some avoided severe precipitated withdrawal. Four patients completed initiation over four days with only mild symptoms. Two patients experienced cognitive changes at higher doses. The protocol suggests ketamine can lower barriers to buprenorphine treatment, but further research is needed.
Addiction science & clinical practice
February 4, 2026
Maya Appley, Jessica R Gray, Dima Abdulrahim et al.
1 citation
A young woman with severe post-traumatic stress disorder developed a severe ketamine use disorder, along with gastrointestinal toxicity and uropathy from chronic use. A multidisciplinary care plan, modeled on a UK clinic for club drug users, included specialist referrals for physical complications and mental health support. With this approach, she significantly reduced ketamine use for a time. US healthcare providers need awareness of non-medical ketamine use and its harms to counsel and treat the growing number of users. The UK's multidisciplinary clinic offers a model for patient-centered care that could inform US systems.
Addiction science & clinical practice
July 21, 2025
Patricia A Cioe, Garrett S Stang, Danish Azam et al.
1 citation
People with HIV (PWH) smoke cigarettes at high rates (40–70%) and often struggle to quit with standard treatments, partly due to anxiety and depression. Psilocybin, a psychedelic designated as breakthrough therapy by the FDA, has shown promise for psychiatric symptoms and substance use disorders, including tobacco dependence; a pilot study reported 80% smoking abstinence at 6 months among people who had previously been unable to quit. In qualitative interviews with 25 PWH who smoke, five themes emerged: varied prior psilocybin experiences, uncertainty about its effects and side effects, need for trusted information and testimonials, willingness to try psilocybin-assisted therapy for tobacco treatment, and importance of the setting. Psilocybin-assisted smoking cessation treatment appears acceptable to PWH who smoke, though concerns must be addressed before it can be incorporated into clinical services.